Infection-resistant medical devices

Surgery – Means for introducing or removing material from body for... – Treating material introduced into or removed from body...

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

Reexamination Certificate

active

07322965

ABSTRACT:
A method for preventing medical device-associated microorganism infection includes the steps of providing a medical device and incorporating an effective amount of an oxazolidinone compound, such as linezolid, into the medical device.

REFERENCES:
patent: 4723950 (1988-02-01), Lee
patent: 5055455 (1991-10-01), Pier
patent: 5624704 (1997-04-01), Darouichenet et al.
patent: 5688792 (1997-11-01), Barbachyn et al.
patent: 6719991 (2004-04-01), Darouiche et al.
patent: 2003/0176848 (2003-09-01), Gibson
patent: 2003/0219461 (2003-11-01), Britten
patent: 2145961 (2000-02-01), None
patent: WO 95/21636 (1995-08-01), None
patent: WO 98/46287 (1998-10-01), None
patent: WO03007870 (2003-01-01), None
patent: WO03061715 (2003-07-01), None
patent: WO03097159 (2003-11-01), None
patent: WO2004014392 (2004-02-01), None
Raad et al “Staphylococcus epidermis: Emerging Resistance and Need for Alternative Agents” (1998) Clinical Infectious Diseases. The University of Chicago 26: 1182-7.
Lizondo et al. “Linezoid” Druges of the Future. (1996) Prous Science Publishers. 21(11): 1116-1123.
Ford et al “In Vivo Activities of U-100592 and U-100766, Novel Oxazolidinone Antimicrobial Agents against Experimental Bacterial Infection” Jun. 1996 vol. 40 Issue 6. pp. 1508-1513.
International Preliminary Examination Report for Application No. PCT/US03/.01710 dated Jan. 28, 2004.
Written Opinion for Application No. PCT/US03/01710, dated Sep. 29, 2003.
International Search Report for Application No. PCT/US03/01710, dated May 19, 2003.
Paradisi, et al., “Antistaphylococcal (MSSA, MRSA, MSSE, MRSE) Antibiotics,” inMedical Clinics of North America, Antibiotic Therapy, Part II, vol. 85, Jan. 2001.
“Linezolid: Oxazolidinone Antibacterial” inDrugs of the Future, vol. 21, 1996.
Raad, et al., “Staphylococcus epidermis: Emerging Resistance and Need for Alternative Agents,”Clinical Infectious Diseases, 1998; 26: 1182-1187.
G. Zerah, et al., “Prevention of Infection Related to Pacemaker Implantation Using Laser Surgery and Prophylactic Antibiotics in a Series of 1184 Patients,”Pacing and Clinical Electrophysiology, vol. 20, Part 2, Sep. 1, 1997.
National Committee for Clinical Laboratory Standards,Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard—Fifth Edition(2000).
Mittelman, “Recovery and Characterization of Biofilm Bacteria Associated with Medical Devices,” inMethods in Enzymology, vol. 310, Biofilms, 1999; 534-536.
Cramton, et al., “The Intercellular Adhesion (ica) Locus is Present inStaphylococcus aureusand Is Required for Biofilm Formation,”Infect. Immun.1999; 67:5427-5433.
Projan, et al., “The Molecular Basis of Pathogenicity,” inThe Staphylococci in Human Disease, 1997, 55-81.
Rupp, “Infections of Intravascular Catheters and Vascular Devices,” inThe Staphylococci in Human Disease, 1997; 379-399.
Mittelman, “Adhesion to Biomaterials,” inBacterial Adhesion: Molecular and Ecological Diversity, 1996; 89-127.
Costerton, “Introduction to Biofilm,”Int. J. Antimicrob. Agents, 1999; 11:217-221.
Rupp, et al., “Characterization of the Importance of Polysaccharide Intercellular Adhesin/Hemagglutinin ofStaphylococcus epidermidisin the Pathogenesis of Biomaterial-Based Infection in a Mouse Foreign Body Infection Model,”Infect. Immun., 1999; 67(5):2627-2632.
Gristina, “Biomaterial-Centered Infection: Microbial Adhesion Versus Tissue Integration,”Science, 1987; 237:1588-1595.
Bisognano, et al., “Increases Expression of Fibronectin-Binding Proteins by Fluoroquinolone-ResistantStaphylococcus aureusExposed to Subinhibitory Levels of Ciprofloxacin,”Antimicrob. Agents Chemother., 1997; 41(5):906-913.
Rupp, et al., “Characterization ofStaphylococcus epidermidisPolysaccharide Intercellular Adhesin/Hemagglutinin in the Pathogenesis of Intravascular Catheter-Associated Infection in a Rat Model,”Infect. Immun., 1999; 67(5):2656-2659.
Clemett, et al., “Linezolid: New Drug Profile,”Drugs, 2000; 59(4):815-827.
Shinabarger, “Mechanism of Action of the Oxazolidinone Antibacterial Agents,”Expert Opin. Invest. Drug., 1999; 8:1195-1202.
Davenport, et al., “Usefulness of a Test for Slime Production as a Marker for Clinically Significant Infections with Coagulase-Negative Staphyloccoci,”J. Infect. Dis., 1986; 153(2):332-339.
Deighton, et al., “Adherence Measured by Microtiter Assay as a Virulence Marker forStaphylococcus epidermidisInfections,”J. Clin. Microbiol., 1990; 28(11);2442-2447.
Christensen, et al., “Adherence of Coagulase-Negative Staphylococci to Plastic Tissue Culture Plates: A Quantitative Model for the Adherence of Staphylococci to Medical Devices,”J. Clin. Microbiol., 1985; 22(6):996-1006.
Khardori, et al., “Effect of Subinhibitory Concentrations of Clindamycin and Trospectomycin on the Adherence ofStaphylococcus epidermidisin an In Vitro Model of Vascular Catheter Colonization,”J. Infect. Dis., 1991, 164:108-113.
Rachid, et al., “Effect of Subinhibitory Antibiotic Concentrations on Polysaccharide Intercellular Adhesin Expression in Biofilm-FormingStaphylococcus epidermidis,”Antimicrob. Agents Chemother., 2000; 44(12):3357-3363.
Schifferli, et al., “Bacterial Adhesion: Modulation by Antibiotics Which Perturb Protein Synthesis,”Antimicrob. Agents Chemother., 1988; 32(11):1603-1608.
Shibl, “Influence of Subinhibitory Concentrations of Antibiotics on Virulence of Staphylococci,”Rev. Infect. Dis., 1987; 9(4):704-712.
Carsenti-Etesse, et al., “Effects of Subinhibitory Concentrations of Vancomycin and Teicoplanin on Adherence of Staphylococci to Tissue Culture Plates,”Antimicrob. Agents Chemother., 1993; 37(4):921-923.
Rupp, et al., “Effect of Subinhibitory Concentrations of Vancomycin, Cefazolin, Ofloxacin, L-Ofloxacin and D-Ofloxacin on Adherence to Intravascular Catheters and Biofilm Formation byStaphylococcus epidermidis,”J. Antimicrob. Chemother., 1998; 41:155-161.
Schadow, et al., “Characteristics of Adherence to Plastic Tissue Culture Plates of Coagulase-Negative Staphylococci Exposed to Subinhibitory Concentrations of Antimicrobial Agents,”J. Infect. Dis., 1988; 157(1):71-77.
Wilcox et al., “Effects of Carbon Dioxide and Sub-Lethal Levels of Antibiotics on Adherence of Coagulase-Negative Staphylococci to Polystyrene and Silicone Rubber,”J. Antimicrob. Chemother.1991; 27:577-587.
Mermei, L A. et al., Guildelines for the Management fo Intravascular Catheter-Related Infections, Clinical Infectious Deseases, 2001: 32:1249-72.
Cammarata, Sue K et al., Incidence of intravenous catheter-related complications during clinical trials of linezolid, an oxazolidinone., Clinical Infectious Diseases, 31(1), Jul. 2000. 225.
Leach T S et al, Clinical efficacy of linezolid for infections caused by vancomycin-resistant enterococci (VRE) in a compassionate-use program. Clinical Infectious Diseases. vol. 31(1), 224, 2000.
Birmingham M C et al., Treating outpatients (outpts) with significant, resistant Gram-positive infectious with linezolid (LNZ). Clinical Infectious Diseases, vol. 31(1), 224, 2000.
Chien J W et al., Use of linezolid, an oxazolidinone, in the treatment of multidrug-resistant gram-positive bacterial infections. Clinical Infectious Diseases vol. 30(1), pp. 146-151, 2000.
McNeil S A et al., Successful treatment of vancomycin-resistantEnterococcus faeciumbacteremia with linezolid after failure of treatment with Synercid (quinupristin/dalfopristin). Clinical Infectious Diseases, vol. 30(2) pp. 403-404, 2000.
Smith P F, et al., Clinical outcomes (CO), safety and tolerance of linezolid (LZD) for resistant Gram-positive (G+) infections in patients with neutropenia. Clinical Infectious Diseases, vol. 29(4), p. 960, 1999.
McGahee W, et al., Staphylococcal infections in the

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Infection-resistant medical devices does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Infection-resistant medical devices, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Infection-resistant medical devices will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-2801699

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.